Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix tablets for androgen-sensitive advanced prostate cancer
ChiCTR2400087806Phase 3Completed
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tissue-plasminogen activator in prostate cancer (PCa), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Sustained castration rate of serum testosterone. Started Aug 2024; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400087806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087806.